| The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo KL Meerbrey, G Hu, JD Kessler, K Roarty, MZ Li, JE Fang, JI Herschkowitz, ... Proceedings of the National Academy of Sciences 108 (9), 3665-3670, 2011 | 703 | 2011 |
| Acetylation of Smc3 by Eco1 is required for S phase sister chromatid cohesion in both human and yeast J Zhang, X Shi, Y Li, BJ Kim, J Jia, Z Huang, T Yang, X Fu, SY Jung, ... Molecular cell 31 (1), 143-151, 2008 | 470 | 2008 |
| Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation YC Wang, G Morrison, R Gillihan, J Guo, RM Ward, X Fu, MF Botero, ... Breast Cancer Research 13, 1-19, 2011 | 301 | 2011 |
| Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer CJ Creighton, X Fu, BT Hennessy, AJ Casa, Y Zhang, ... Breast cancer research 12, 1-12, 2010 | 300 | 2010 |
| An epigenomic approach to therapy for tamoxifen-resistant breast cancer Q Feng, Z Zhang, MJ Shea, CJ Creighton, C Coarfa, SG Hilsenbeck, ... Cell research 24 (7), 809-819, 2014 | 214 | 2014 |
| Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI (3, 4, 5) P3 production Y Zhang, CC Tseng, YL Tsai, X Fu, R Schiff, AS Lee PloS one 8 (11), e80071, 2013 | 168 | 2013 |
| FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, ... Proceedings of the National Academy of Sciences 113 (43), E6600-E6609, 2016 | 152 | 2016 |
| Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance XY Fu, HY Wang, L Tan, SQ Liu, HF Cao, MC Wu World journal of gastroenterology 8 (4), 638, 2002 | 137 | 2002 |
| Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma H Li, X Fu, Y Chen, Y Hong, Y Tan, H Cao, M Wu, H Wang Gastroenterology 128 (7), 2029-2041, 2005 | 125 | 2005 |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ... Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019 | 123 | 2019 |
| Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy M Giuliano, H Hu, YC Wang, X Fu, A Nardone, S Herrera, S Mao, ... Clinical Cancer Research 21 (17), 3995-4003, 2015 | 118 | 2015 |
| Embryonic transcription factor SOX9 drives breast cancer endocrine resistance R Jeselsohn, MI Cornwell, M Pun, G Buchwalter, M Nguyen, C Bango, ... Proceedings of the National Academy of Sciences 114 (22), E4482-E4491, 2017 | 110 | 2017 |
| Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer X Fu, CK Osborne, R Schiff The Breast 22, S12-S18, 2013 | 106 | 2013 |
| Tamoxifen resistance in breast cancer is regulated by the EZH2–ERα–GREB1 transcriptional axis Y Wu, Z Zhang, ME Cenciarini, CJ Proietti, M Amasino, T Hong, M Yang, ... Cancer research 78 (3), 671-684, 2018 | 95 | 2018 |
| Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance M Bi, Z Zhang, YZ Jiang, P Xue, H Wang, Z Lai, X Fu, C De Angelis, ... Nature cell biology 22 (6), 701-715, 2020 | 87 | 2020 |
| Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or … X Fu, CJ Creighton, NC Biswal, V Kumar, M Shea, S Herrera, A Contreras, ... Breast Cancer Research 16, 1-17, 2014 | 84 | 2014 |
| RFWD3–Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage X Fu, N Yucer, S Liu, M Li, P Yi, JJ Mu, T Yang, J Chu, SY Jung, ... Proceedings of the National Academy of Sciences 107 (10), 4579-4584, 2010 | 84 | 2010 |
| Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance N Putluri, S Maity, R Kommagani, CJ Creighton, V Putluri, F Chen, ... Neoplasia 16 (5), 390-402, 2014 | 80 | 2014 |
| PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells G Buchwalter, MM Hickey, A Cromer, LM Selfors, RN Gunawardane, ... Cancer cell 23 (6), 753-767, 2013 | 72 | 2013 |
| Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance G Morrison, X Fu, M Shea, S Nanda, M Giuliano, T Wang, T Klinowska, ... Breast cancer research and treatment 144, 263-272, 2014 | 63 | 2014 |
